Aptose Biosciences DEF 14A: Executive Comp & Equity Awards
Ticker: APTOF · Form: DEF 14A · Filed: Apr 28, 2025 · CIK: 882361
Sentiment: neutral
Topics: executive-compensation, equity-awards, proxy-statement
TL;DR
Aptose Biosciences DEF 14A out: Executive pay and stock awards for 2023-2024 detailed.
AI Summary
Aptose Biosciences Inc. filed a DEF 14A on April 28, 2025, for the period ending May 27, 2025. The filing details executive compensation and equity awards for the fiscal years ending December 31, 2023, and December 31, 2024. It includes information on changes in the fair value of outstanding equity awards and those that vested during these periods.
Why It Matters
This filing provides insight into how Aptose Biosciences Inc. compensates its top executives and the value of equity awards granted, which can impact shareholder value and company performance.
Risk Assessment
Risk Level: medium — DEF 14A filings related to executive compensation can signal potential changes in management's outlook or financial health, influencing investor confidence.
Key Numbers
- 2023-12-31 — Fiscal Year End (Reporting period for equity awards)
- 2024-12-31 — Fiscal Year End (Reporting period for equity awards)
Key Players & Entities
- Aptose Biosciences Inc. (company) — Filer
- Lorus Therapeutics Inc. (company) — Former Company Name
- Imutec Pharma Inc (company) — Former Company Name
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide detailed information regarding the solicitation of proxies for the company's annual meeting of stockholders, including executive compensation and related matters.
What specific fiscal years are covered by the equity award information in this filing?
The filing covers equity award information for the fiscal years ending December 31, 2023, and December 31, 2024.
What types of equity awards are detailed in the filing?
The filing details changes in the fair value of outstanding and unvested equity awards granted in prior years, as well as equity awards granted and vested in the covered years.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 28, 2025.
What was Aptose Biosciences Inc. formerly known as?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and prior to that, Imutec Pharma Inc.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 28, 2025 regarding Aptose Biosciences Inc. (APTOF).